Quick Takeaways
- Crystal Peak Investment Inc. filed SCHEDULE 13D/A for LakeShore Biopharma Co., Ltd. Ordinary Shares, par value $0.0002 per share (LSBCF).
- Disclosed ownership: 51%.
- Date of event: 29 Apr 2026.
Crystal Peak Investment Inc. - 29 Apr 2026 SCHEDULE 13D/A Report for LakeShore Biopharma Co., Ltd. Ordinary Shares, par value $0.0002 per share (LSBCF)
- Filing Manager
- Crystal Peak Investment Inc.
- Reporting Manager
- Crystal Peak Investment Inc.
- Symbol
- LSBCF
- Shares outstanding
- 41,218,298 shares
- Disclosed Ownership
- 21,021,332 shares
- Ownership
- 51%
- Form type
- SCHEDULE 13D/A
- Filing time
- 29 Apr 2026, 09:08:03 UTC
- Date of event
- 29 Apr 2026
- Previous filing
- 25 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Crystal Peak Investment Inc. disclosed 51% ownership in LakeShore Biopharma Co., Ltd. Ordinary Shares, par value $0.0002 per share (LSBCF) on 29 Apr 2026."
What Changed
- Previous schedule filing date: 25 Mar 2026.
- Current filing was accepted on 29 Apr 2026, 09:08.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (15)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Huaqin Xue | 51% | 21,021,332 | 21,021,332 | 0 | /s/ Huaqin Xue | Huaqin Xue | |
| Crystal Peak Holdings Inc. | 51% | 21,021,332 | 21,021,332 | 0 | /s/ Huaqin Xue | Huaqin Xue/Director | |
| Crystal Peak Investment Inc. | 51% | 21,021,332 | 21,021,332 | 0 | /s/ Huaqin Xue | Huaqin Xue/Director | 0002078050 |
| Dave Liguang Chenn | 1.1% | 462,760 | 462,760 | 0 | /s/ Dave Liguang Chenn | Dave Liguang Chenn | |
| Oceanpine Investment Fund II LP | 1% | 410,560 | 410,560 | 0 | /s/ Dave Liguang Chenn | Dave Liguang Chenn/Director | |
| Oceanpine Capital Inc. | 0.1% | 52,200 | 52,200 | 0 | /s/ Jiayu Yang | Jiayu Yang/Director | |
| Adjuvant Capital Management, L.L.C. | 0.7% | 290,298 | 0 | 290,298 | /s/ Kabeer Aziz | Kabeer Aziz/Vice President & Secretary | |
| Adjuvant Capital GP, L.P. | 0.7% | 290,298 | 0 | 290,298 | /s/ Kabeer Aziz | Kabeer Aziz/Vice President & Secretary | |
| Adjuvant Global Health Technology Fund, L.P. | 0.59% | 243,630 | 0 | 243,630 | /s/ Kabeer Aziz | Kabeer Aziz/Vice President & Secretary | |
| Adjuvant Global Health Technology Fund DE, L.P. | 0.11% | 46,668 | 0 | 46,668 | /s/ Kabeer Aziz | Kabeer Aziz/Vice President & Secretary | |
| MSA China Growth Fund II GP, LLC | 0.27% | 112,904 | 112,904 | 0 | /s/ Yu (Jenny) Zeng | Yu (Jenny) Zeng/Manager | |
| MSA Growth Fund II, L.P. | 0.27% | 112,904 | 112,904 | 0 | /s/ Yu (Jenny) Zeng | Yu (Jenny) Zeng/Managing Partner | |
| Superstring Capital Management LP | 0.07% | 30,792 | 30,792 | 0 | /s/ Ting Guo | Ting Guo/Managing Partner | |
| Superstring Capital Master Fund LP | 0.07% | 30,792 | 30,792 | 0 | /s/ Ting Guo | Ting Guo/General Partner | |
| Epiphron Capital (Hong Kong) Limited | 0.17% | 70,083 | 70,083 | 0 | /s/ Sherry Xiaoyu Liu | Sherry Xiaoyu Liu/Director |